Literature DB >> 31036685

Activity of Antibiotics against Staphylococcus aureus in an In Vitro Model of Biofilms in the Context of Cystic Fibrosis: Influence of the Culture Medium.

Yvan Diaz Iglesias1, Tobias Wilms2, Rita Vanbever2, Françoise Van Bambeke3.   

Abstract

Staphylococcus aureus is a highly prevalent pathogen in the respiratory tract of young patients with cystic fibrosis (CF) and causes biofilm-related infections. Here, we set up an in vitro model of a biofilm grown in Trypticase soy broth supplemented with glucose and NaCl (TGN) or in artificial sputum medium (ASM) and used it to evaluate on a pharmacodynamic basis the activity of antibiotics used in CF patients and active on staphylococci (meropenem, vancomycin, azithromycin, linezolid, rifampin, ciprofloxacin, tobramycin). Rheological studies showed that ASM was more elastic than viscous, as was also observed for sputa from CF patients, with elastic and viscous moduli being, respectively, similar to and slightly lower than those of CF sputa. Biofilms formed by methicillin-sensitive S. aureus strain ATCC 25923 and methicillin-resistant S. aureus strain ATCC 33591 reached maturity after 24 h, with biomass (measured by crystal violet staining) and metabolic activity (assessed by following resazurin metabolization) being lower in ASM than in TGN and viability (assessed by bacterial counts) being similar in both media. Full concentration-response curves of antibiotics obtained after 24 h of incubation of biofilms showed that all antibiotics were drastically less potent and less efficient in ASM than in TGN toward viability, metabolic activity, and biomass. Tobramycin selected for small-colony variants, specifically in biofilms grown in ASM; the auxotrophism of these variants could not be established. These data highlight the major influence exerted by the culture medium on S. aureus responsiveness to antibiotics in biofilms. The use of ASM may help to determine effective drug concentrations or to evaluate new therapeutic options against biofilms in CF patients.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  Staphylococcus aureus; antibiotics; biofilms; cystic fibrosis; small-colony variants

Year:  2019        PMID: 31036685      PMCID: PMC6591632          DOI: 10.1128/AAC.00602-19

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  50 in total

1.  Screening a repurposing library for potentiators of antibiotics against Staphylococcus aureus biofilms.

Authors:  Freija Van den Driessche; Gilles Brackman; Rosalie Swimberghe; Petra Rigole; Tom Coenye
Journal:  Int J Antimicrob Agents       Date:  2017-01-31       Impact factor: 5.283

Review 2.  Antimicrobial resistance, respiratory tract infections and role of biofilms in lung infections in cystic fibrosis patients.

Authors:  Oana Ciofu; Tim Tolker-Nielsen; Peter Østrup Jensen; Hengzhuang Wang; Niels Høiby
Journal:  Adv Drug Deliv Rev       Date:  2014-12-02       Impact factor: 15.470

3.  Triclosan-induced aminoglycoside-tolerant Listeria monocytogenes isolates can appear as small-colony variants.

Authors:  Vicky G Kastbjerg; Line Hein-Kristensen; Lone Gram
Journal:  Antimicrob Agents Chemother       Date:  2014-03-17       Impact factor: 5.191

Review 4.  Review: Staphylococcus aureus and MRSA in cystic fibrosis.

Authors:  Christopher H Goss; Marianne S Muhlebach
Journal:  J Cyst Fibros       Date:  2011-06-29       Impact factor: 5.482

5.  Virulent gentamicin-induced small colony variants of Staphylococcus aureus.

Authors:  L L Pelletier; M Richardson; M Feist
Journal:  J Lab Clin Med       Date:  1979-08

6.  Pros and cons of using resazurin staining for quantification of viable Staphylococcus aureus biofilms in a screening assay.

Authors:  Malena E Sandberg; Denise Schellmann; Gerda Brunhofer; Thomas Erker; Igor Busygin; Reko Leino; Pia M Vuorela; Adyary Fallarero
Journal:  J Microbiol Methods       Date:  2009-05-08       Impact factor: 2.363

Review 7.  Prevention and treatment of Staphylococcus aureus biofilms.

Authors:  Mohini Bhattacharya; Daniel J Wozniak; Paul Stoodley; Luanne Hall-Stoodley
Journal:  Expert Rev Anti Infect Ther       Date:  2015-11-13       Impact factor: 5.091

Review 8.  Micro- and macrorheology of mucus.

Authors:  Samuel K Lai; Ying-Ying Wang; Denis Wirtz; Justin Hanes
Journal:  Adv Drug Deliv Rev       Date:  2009-01-03       Impact factor: 15.470

9.  Activities of Combinations of Antistaphylococcal Antibiotics with Fusidic Acid against Staphylococcal Biofilms in In Vitro Static and Dynamic Models.

Authors:  Wafi Siala; Hector Rodriguez-Villalobos; Prabhavathi Fernandes; Paul M Tulkens; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

10.  Quantification of Pseudomonas aeruginosa in multispecies biofilms using PMA-qPCR.

Authors:  Sarah Tavernier; Tom Coenye
Journal:  PeerJ       Date:  2015-02-24       Impact factor: 2.984

View more
  3 in total

1.  Pharmacodynamics of Moxifloxacin, Meropenem, Caspofungin, and Their Combinations against In Vitro Polymicrobial Interkingdom Biofilms.

Authors:  Albert Ruiz-Sorribas; Hervé Poilvache; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2021-12-20       Impact factor: 5.938

2.  Activity of Antibiotics against Pseudomonas aeruginosa in an In Vitro Model of Biofilms in the Context of Cystic Fibrosis: Influence of the Culture Medium.

Authors:  Yvan Diaz Iglesias; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

3.  Comparative evaluation of the effect of different growth media on in vitro sensitivity to azithromycin in multi-drug resistant Pseudomonas aeruginosa isolated from cystic fibrosis patients.

Authors:  Michael Sörensen; Bakhodur Khakimov; Dennis Nurjadi; Sébastien Boutin; Buqing Yi; Alexander H Dalpke; Tatjana Eigenbrod
Journal:  Antimicrob Resist Infect Control       Date:  2020-12-09       Impact factor: 4.887

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.